Abstract
Encouraging response rates and survival have been reported with intra- arterial (i.a.) chemotherapy and chemoembolization, but limited data are available on the association of the two treatment modalities. We therefore started a feasibility study of i.a. chemotherapy plus chemoembolization, performed every 28 days for 3 cycles, according to the following schedule: L-leucovorin (100 mg/m 2 i.v.), fluorouracil (800 mg/m 2 i.a.), and carboplatin (250 mg/m 2 i.a.). Chemoembolization with mitoxantrone (10 mg/m 2) plus ethiodized oil was performed immediately after this treatment, followed by gelatin powder. Fourteen patients entered the study and were evaluable for side effects. Main patient characteristics were: males 13, females 1; median age 65 yr (range 45-75); stage TNM II-III 10, IVA 4; Childs' A 8, Childs' B 6; elevated baseline α-fetoprotein, 11; cirrhosis 14. No drug-related deaths have been observed. Ten patients were able to complete the program. The reasons for discontinuing treatment were worsening of liver functions in 3 cases and grade IV neutropenia in 1 patient. Eight patients had grade I-II pain and 10 patients had grade I-II fever. In conclusion the study demonstrated that chemoembolization plus i.a. chemotherapy is feasible in patients with hepatocellular carcinoma in cirrhosis and deserves further investigation.
| Original language | English |
|---|---|
| Pages (from-to) | 879-882 |
| Number of pages | 4 |
| Journal | Oncology Reports |
| Volume | 3 |
| Issue number | 5 |
| Publication status | Published - Sep 1996 |
Fingerprint
Keywords
- chemoembolization
- hepatocellular carcinoma
- intra-arterial chemotherapy
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Feasibility of intra-arterial chemotherapy followed by chemoembolization, every 28 days, in unresectable hepatocellular carcinoma. / Colleoni, Marco; Liessi, Guido; Mastrapasqua, Giorgio; Nelli, Patrizia; Vicario, Giovanni; Sgarbossa, Gigliola; Pancheri, Francesca; Manente, Paolo.
In: Oncology Reports, Vol. 3, No. 5, 09.1996, p. 879-882.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Feasibility of intra-arterial chemotherapy followed by chemoembolization, every 28 days, in unresectable hepatocellular carcinoma
AU - Colleoni, Marco
AU - Liessi, Guido
AU - Mastrapasqua, Giorgio
AU - Nelli, Patrizia
AU - Vicario, Giovanni
AU - Sgarbossa, Gigliola
AU - Pancheri, Francesca
AU - Manente, Paolo
PY - 1996/9
Y1 - 1996/9
N2 - Encouraging response rates and survival have been reported with intra- arterial (i.a.) chemotherapy and chemoembolization, but limited data are available on the association of the two treatment modalities. We therefore started a feasibility study of i.a. chemotherapy plus chemoembolization, performed every 28 days for 3 cycles, according to the following schedule: L-leucovorin (100 mg/m 2 i.v.), fluorouracil (800 mg/m 2 i.a.), and carboplatin (250 mg/m 2 i.a.). Chemoembolization with mitoxantrone (10 mg/m 2) plus ethiodized oil was performed immediately after this treatment, followed by gelatin powder. Fourteen patients entered the study and were evaluable for side effects. Main patient characteristics were: males 13, females 1; median age 65 yr (range 45-75); stage TNM II-III 10, IVA 4; Childs' A 8, Childs' B 6; elevated baseline α-fetoprotein, 11; cirrhosis 14. No drug-related deaths have been observed. Ten patients were able to complete the program. The reasons for discontinuing treatment were worsening of liver functions in 3 cases and grade IV neutropenia in 1 patient. Eight patients had grade I-II pain and 10 patients had grade I-II fever. In conclusion the study demonstrated that chemoembolization plus i.a. chemotherapy is feasible in patients with hepatocellular carcinoma in cirrhosis and deserves further investigation.
AB - Encouraging response rates and survival have been reported with intra- arterial (i.a.) chemotherapy and chemoembolization, but limited data are available on the association of the two treatment modalities. We therefore started a feasibility study of i.a. chemotherapy plus chemoembolization, performed every 28 days for 3 cycles, according to the following schedule: L-leucovorin (100 mg/m 2 i.v.), fluorouracil (800 mg/m 2 i.a.), and carboplatin (250 mg/m 2 i.a.). Chemoembolization with mitoxantrone (10 mg/m 2) plus ethiodized oil was performed immediately after this treatment, followed by gelatin powder. Fourteen patients entered the study and were evaluable for side effects. Main patient characteristics were: males 13, females 1; median age 65 yr (range 45-75); stage TNM II-III 10, IVA 4; Childs' A 8, Childs' B 6; elevated baseline α-fetoprotein, 11; cirrhosis 14. No drug-related deaths have been observed. Ten patients were able to complete the program. The reasons for discontinuing treatment were worsening of liver functions in 3 cases and grade IV neutropenia in 1 patient. Eight patients had grade I-II pain and 10 patients had grade I-II fever. In conclusion the study demonstrated that chemoembolization plus i.a. chemotherapy is feasible in patients with hepatocellular carcinoma in cirrhosis and deserves further investigation.
KW - chemoembolization
KW - hepatocellular carcinoma
KW - intra-arterial chemotherapy
UR - http://www.scopus.com/inward/record.url?scp=0029787817&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029787817&partnerID=8YFLogxK
M3 - Article
VL - 3
SP - 879
EP - 882
JO - Oncology Reports
JF - Oncology Reports
SN - 1021-335X
IS - 5
ER -